Home › NDC Lookup › RxCUI directory › RxCUI 2607533

Lumateperone 21 MG Oral Capsule — RxCUI 2607533

RxNorm drug concept · Semantic clinical drug
RxCUI 2607533 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2607533
Official nameLumateperone 21 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aslumateperone 21 MG (as lumateperone tosylate 30 MG) Oral Capsule
FDA products mapped3
Package NDCs mapped6
Reported Medicaid activity (SDUD)251,587 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lumateperone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • You're right on both counts — lumateperone (Caplyta) is classified as an atypical antipsychotic, but it's approved for more than just schizophrenia. It's also approved to treat the...
  • What exactly is Caplyta used for? My doctor prescribed it for depression, but I thought it was an antipsychotic.
  • Drowsiness and sedation are among the most common side effects, especially early on. Many people find this improves over time as their body adjusts. It's worth giving it a few week...
  • Will Caplyta make me really drowsy? I can't afford to be foggy at work.
📖 Read our full Lumateperone guide →

🕸️ Concept Web — How Lumateperone 21 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lumateperone 21 MG Oral Capsule RxCUI 2607533

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lumateperone 2275602
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Caplyta 2275608
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lumateperone Oral Capsule 2275606
    • Lumateperone Oral Product 2619251
    • Lumateperone Pill 2619250
    • Lumateperone Oral Capsule [Caplyta] 2275610
    • Caplyta Oral Product 2275611
    • Caplyta Pill 2275612
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lumateperone 21 MG SCDC · 2619058
  • Lumateperone Oral Capsule SCDF · 2275606
  • Lumateperone Oral Product SCDG · 2619251
  • Lumateperone Pill SCDG · 2619250

Brand-Name Concepts

  • Lumateperone 21 MG Oral Capsule [Caplyta] SBD · 2607535
  • Lumateperone 21 MG [Caplyta] SBDC · 2619060
  • Lumateperone Oral Capsule [Caplyta] SBDF · 2275610
  • Caplyta Oral Product SBDG · 2275611
  • Caplyta Pill SBDG · 2275612
  • Caplyta BN · 2275608

📦 FDA Products & Package NDCs

3 products · 6 package NDCs
6 package NDCs map to RxCUI 2607533 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
72060-0110-07 7 CAPSULE in 1 BOTTLE (72060-110-07) CAPLYTA Intra-Cellular Therapies, Inc 2023-06-01
72060-0110-40 30 CAPSULE in 1 BOTTLE (72060-110-40) CAPLYTA Intra-Cellular Therapies, Inc 2022-08-09
72060-0121-07 7 CAPSULE in 1 BOTTLE (72060-121-07) CAPLYTA Intra-Cellular Therapies, Inc 2023-06-01
72060-0121-40 30 CAPSULE in 1 BOTTLE (72060-121-40) CAPLYTA Intra-Cellular Therapies, Inc 2022-08-09
72060-0142-07 7 CAPSULE in 1 BOTTLE (72060-142-07) CAPLYTA Intra-Cellular Therapies, Inc 2021-11-01
72060-0142-40 30 CAPSULE in 1 BOTTLE (72060-142-40) CAPLYTA Intra-Cellular Therapies, Inc 2022-04-01
Observed labelers: Intra-Cellular Therapies, Inc (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.